Therefore, targeting on energy metabolism including inhibitors of glycogen synthase kinase 3 beta (GSK-3β), which was considered as milestones in the treatments of HF after AMI, are extensively investigated (Takahashiyanaga, 2013). Here, GSK3B is linked to hydrops fetalis.